Related references
Note: Only part of the references are listed.L-Theanine Relieves Positive, Activation, and Anxiety Symptoms in Patients With Schizophrenia and Schizoaffective Disorder: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, 2-Center Study
Michael S. Ritsner et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
N-methyl-D-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia?
Joshua T. Kantrowitz et al.
BRAIN RESEARCH BULLETIN (2010)
Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis
Surendra P. Singh et al.
BRITISH JOURNAL OF PSYCHIATRY (2010)
Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis
Guochuan E. Tsai et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia
Hsien-Yuan Lane et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia
Vidhi Singh et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Lack of Association Between Serum Brain-Derived Neurotrophic Factor Levels and Improvement of Schizophrenia Symptoms in a Double-Blind, Randomized, Placebo-Controlled Trial of Memantine as Adjunctive Therapy to Clozapine
David de Lucena et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Selective GlyT1 Inhibitors: Discovery of [4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a Promising Novel Medicine To Treat Schizophrenia
Emmanuel Pinard et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Functional 'glial' GLYT1 glycine transporters expressed in neurons
Luca Raiteri et al.
JOURNAL OF NEUROCHEMISTRY (2010)
The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects
M. Liem-Moolenaar et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis
J. Daumann et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects
M. Liem-Moolenaar et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
Decreased glutathione levels and altered antioxidant defense in an animal model of schizophrenia: Long-term effects of perinatal phencyclidine administration
Nevena V. Radonjic et al.
NEUROPHARMACOLOGY (2010)
The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia
Viviane Labrie et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2010)
Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant
R. Hwang et al.
PHARMACOGENOMICS JOURNAL (2010)
Glycine and glycine receptor signaling in hippocampal neurons: Diversity, function and regulation
Tian-Le Xu et al.
PROGRESS IN NEUROBIOLOGY (2010)
Plasma alanine levels increase in patients with schizophrenia as their clinical symptoms improve-Results from the Juntendo University Schizophrenia Projects (JUSP)
Tokiko Hatano et al.
PSYCHIATRY RESEARCH (2010)
High dose D-serine in the treatment of schizophrenia
Joshua T. Kantrowitz et al.
SCHIZOPHRENIA RESEARCH (2010)
Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update
C. Chaves et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2009)
Pharmacological Manipulation of Kynurenic Acid Potential in the Treatment of Psychiatric Disorders
Sophie Erhardt et al.
CNS DRUGS (2009)
A Role for Glutathione in the Pathophysiology of Bipolar Disorder and Schizophrenia? Animal Models and Relevance to Clinical Practice
O. M. Dean et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Redox dysregulation, neurodevelopment, and schizophrenia
Kim Q. Do et al.
CURRENT OPINION IN NEUROBIOLOGY (2009)
Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia
Clement C. Zai et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2009)
Improvement of Negative and Positive Symptoms in Treatment-Refractory Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Trial With Memantine as Add-On Therapy to Clozapine
David de Lucena et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine
Hai Xia Zhang et al.
JOURNAL OF PHYSIOLOGY-LONDON (2009)
Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study
C. Lavedan et al.
MOLECULAR PSYCHIATRY (2009)
A putative high risk diplotype of the G72 gene is in healthy individuals associated with better performance in working memory functions and altered brain activity in the medial temporal lobe
Andreas Jansen et al.
NEUROIMAGE (2009)
Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR
Anne-Cecile Fricker et al.
NEUROPHARMACOLOGY (2009)
A nomenclature for ligand-gated ion channels
Graham L. Collingridge et al.
NEUROPHARMACOLOGY (2009)
A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia
Jeffrey A. Lieberman et al.
NEUROPSYCHOPHARMACOLOGY (2009)
DRD4 48bp VNTR but not 5-HT2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain
J. Popp et al.
PHARMACOGENOMICS JOURNAL (2009)
Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia
B. A. Fijal et al.
PHARMACOGENOMICS JOURNAL (2009)
Glutamatergic regulation of serine racemase via reversal of PIP2 inhibition
Asif K. Mustafaa et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors
Shih-Fen Chen et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2009)
Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients
Monia Raffa et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2009)
Association study of the G72 gene with schizophrenia in a Japanese population: A multicenter study
Kazutaka Ohi et al.
SCHIZOPHRENIA RESEARCH (2009)
A possible association between schizophrenia and GRIK3 polymorphisms in a multicenter sample of Scandinavian origin (SCOPE)
S. Djurovic et al.
SCHIZOPHRENIA RESEARCH (2009)
Radical-free biology of oxidative stress
Dean P. Jones
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2008)
Sarcosine (N-Methylglycine) treatment for acute schizophrenia: A randomized, double-blind study
Hsien-Yuan Lane et al.
BIOLOGICAL PSYCHIATRY (2008)
N-acetyl cysteine as a glutathione precursor for schizophrenia - A double-blind, randomized, placebo-controlled trial
Michael Berk et al.
BIOLOGICAL PSYCHIATRY (2008)
Cerebrospinal fluid D-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients
Sabine A. Fuchs et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2008)
Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study
Amir Krivoy et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2008)
D-amino acids in the brain: D-serine in neurotransmission and neurodegeneration
Herman Wolosker et al.
FEBS JOURNAL (2008)
Polypharmacy with Second-Generation Antipsychotics: A Review of Evidence
Anand K. Pandurangi et al.
JOURNAL OF PSYCHIATRIC PRACTICE (2008)
Models of schizophrenia in humans and animals based on inhibition of NMDA receptors
Vera Bubenikova-Valesova et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2008)
Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: Results from the Juntendo University Schizophrenia Projects (JUSP)
Tohru Ohnuma et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2008)
Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy -: a [123I]CNS-1261 SPET study
James M. Stone et al.
PSYCHOPHARMACOLOGY (2008)
No association between the DRD3 Ser9Gly polymorphism and schizophrenia
Ferid Fathalli et al.
SCHIZOPHRENIA RESEARCH (2008)
Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study
Donald C. Goff et al.
SCHIZOPHRENIA RESEARCH (2008)
Initial severity and antidepressant benefits: A meta-analysis of data submitted to the food and drug administration
Irving Kirsch et al.
PLOS MEDICINE (2008)
Acute high-dose glycine attenuates mismatch negativity (MMN) in healthy human controls
Sumie Leung et al.
PSYCHOPHARMACOLOGY (2008)
A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia
Donald C. Goff et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients
Suzie Lavoie et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting
Byungsu Kim et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2008)
Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site
Seong S. Shim et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2007)
Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia
J. Renou et al.
MOLECULAR PSYCHIATRY (2007)
Memantine normalizes brain activity in the inferior frontal gyrus: A controlled pilot fMRI study
Michael A. Cerullo et al.
SCHIZOPHRENIA RESEARCH (2007)
Impaired glutathione synthesis in schizophrenia:: Convergent genetic and functional evidence
Rene Gysin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia
Jean Theberge et al.
BRITISH JOURNAL OF PSYCHIATRY (2007)
The Cognitive and Negative Symptoms in Schizophrenia, Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments
Robert W. Buchanan et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Sandeep T. Patil et al.
NATURE MEDICINE (2007)
Modulation of [3H]dopamine release by glutathione in mouse striatal slices
Reka Janaky et al.
NEUROCHEMICAL RESEARCH (2007)
Homozygosity of the interleukin-10 receptor 1 G330R allele is associated with schizophrenia
Alexandra Schosser et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS (2007)
Evidence from gene knockout studies implicates Asc-1 as the primary transporter mediating D-serine reuptake in the mouse CNS
A. Richard Rutter et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2007)
A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia
Inna Bendikov et al.
SCHIZOPHRENIA RESEARCH (2007)
Glycine transporter I inhibitor, N-methylglycine (Sarcosine), added to clozapine for the treatment of schizophrenia
Hsien-Yuan Lane et al.
BIOLOGICAL PSYCHIATRY (2006)
Schizophrenia and oxidative stress:: Glutamate cysteine ligase modifier as a susceptibility gene
Mirjana Tosic et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
The G72/G30 gene complex and cognitive abnormalities in schizophrenia
Terry E. Goldberg et al.
NEUROPSYCHOPHARMACOLOGY (2006)
Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, D-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1)
Ranjna Kapoor et al.
BRAIN RESEARCH (2006)
Psychological interventions to improve glycaemic control in patients with type 1 diabetes: systematic review and meta-analysis of randomised controlled trials
Kirsty Winkley et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Glutamate and schizophrenia: Beyond the dopamine hypothesis
Joseph T. Coyle
CELLULAR AND MOLECULAR NEUROBIOLOGY (2006)
D-alanine added to antipsychotics for the treatment of schizophrenia
GE Tsai et al.
BIOLOGICAL PSYCHIATRY (2006)
First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients
LS Pilowsky et al.
MOLECULAR PSYCHIATRY (2006)
Serine racemase binds to PICK1: potential relevance to schizophrenia
K Fujii et al.
MOLECULAR PSYCHIATRY (2006)
Regulation of serine racemase activity by D-serine and nitric oxide in human glioblastoma cells
K Shoji et al.
NEUROSCIENCE LETTERS (2006)
Evidence for association of DNA sequence variants in the phosphatidylinositol-4-phosphate 5-kinase II alpha gene (PIP5K2A) with schizophrenia
S. G. Schwab et al.
MOLECULAR PSYCHIATRY (2006)
Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia
HH Holcomb et al.
NEUROPSYCHOPHARMACOLOGY (2005)
A double-blind, cross-over comparison of the effects of amantadine or placebo-on visuomotor and cognitive function in medicated schizophrenia patients
H Silver et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2005)
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia - A randomized, double-blind, placebo-controlled study
HY Lane et al.
ARCHIVES OF GENERAL PSYCHIATRY (2005)
The scaffolding protein PSD-95 interacts with the glycine transporter GLYT1 and impairs its internalization
B Cubelos et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia
T Sumiyoshi et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2005)
Bias and efficiency of meta-analytic variance estimators in the random-effects model
W Viechtbauer
JOURNAL OF EDUCATIONAL AND BEHAVIORAL STATISTICS (2005)
Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine - Implications for glutamatergic and dopaminergic model psychoses and cognitive function
JH Krystal et al.
ARCHIVES OF GENERAL PSYCHIATRY (2005)
Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type
G Neeman et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients
K Hashimoto et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2005)
Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results
P Diaz et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2005)
A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients
DC Goff et al.
PSYCHOPHARMACOLOGY (2005)
D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia
U Heresco-Levy et al.
BIOLOGICAL PSYCHIATRY (2005)
Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: A 4-T proton MRS study
LM Rowland et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Doparnine D3 receptor Ser9GIy polymorphism and risperidone response
HY Lane et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2005)
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
Douglas Faries et al.
BMC PSYCHIATRY (2005)
Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine
DA Yurgelun-Todd et al.
PSYCHIATRY RESEARCH-NEUROIMAGING (2005)
Serine racemase modulates intracellular D-serine levels through an α,β-elimination activity
VN Foltyn et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study
MC Jockers-Scherubl et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2005)
NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in MRI
G Northoff et al.
SCHIZOPHRENIA RESEARCH (2005)
Glycine transporter I inhibitor, N-methylglycine (Sarcosine), added to antipsychotics for the treatment of schizophrenia
GC Tsai et al.
BIOLOGICAL PSYCHIATRY (2004)
Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms
T Sumiyoshi et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2004)
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis
U Heresco-Levy et al.
SCHIZOPHRENIA RESEARCH (2004)
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
U Heresco-Levy et al.
BIOLOGICAL PSYCHIATRY (2004)
Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale
F Salaffi et al.
EUROPEAN JOURNAL OF PAIN (2004)
Effects of D-cycloserine on negative symptoms in schizophrenia
EJ Duncan et al.
SCHIZOPHRENIA RESEARCH (2004)
Variations in the NMDA receptor subunit 2B gene (GRIN2B) and schizophrenia:: A case-control study
E Di Maria et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS (2004)
Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia
B Moghaddam
PSYCHOPHARMACOLOGY (2004)
The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia
JT Coyle et al.
PSYCHOPHARMACOLOGY (2004)
A high prevalence of organ-specific autoimmunity in patients with bipolar disorder
RC Padmos et al.
BIOLOGICAL PSYCHIATRY (2004)
Atypical antipsychotics and the relevance of glutamate and serotonin
FMMA van der Heijden et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2004)
Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: implications for neuroprotection/neurodegeneration?
ME Gegg et al.
JOURNAL OF NEUROCHEMISTRY (2003)
Decreased serum levels of D-serine in patients with schizophrenia - Evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia
K Hashimoto et al.
ARCHIVES OF GENERAL PSYCHIATRY (2003)
A meta-analysis of the efficacy of second-generation antipsychotics
JM Davis et al.
ARCHIVES OF GENERAL PSYCHIATRY (2003)
Structure-function relationship in serine hydroxymethyltransferase
NA Rao et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2003)
The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study
LG Harsing et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2003)
Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo
L Chen et al.
JOURNAL OF NEUROPHYSIOLOGY (2003)
Cofactors of serine racemase that physiologically stimulate the synthesis of the N-methyl-D-aspartate (NMDA) receptor coagonist D-serine
J de Miranda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia
I Chumakov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series
S Marenco et al.
SCHIZOPHRENIA RESEARCH (2002)
D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia
AE Evins et al.
SCHIZOPHRENIA RESEARCH (2002)
Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness
GR Breese et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2002)
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia
U Heresco-Levy et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia
S Erhardt et al.
NEUROSCIENCE LETTERS (2001)
Increased cortical kynurenate content in schizophrenia
R Schwarcz et al.
BIOLOGICAL PSYCHIATRY (2001)
A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia
DC Goff et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2001)
NMDA receptor subunits: diversity, development and disease
S Cull-Candy et al.
CURRENT OPINION IN NEUROBIOLOGY (2001)
Long-term outcome of patients who receive ketamine during research
AC Lahti et al.
BIOLOGICAL PSYCHIATRY (2001)
Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study
M Berk et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2001)
Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence
A Carlsson et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2001)
Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine
A Tortorella et al.
NEUROPSYCHOBIOLOGY (2001)
Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients
DL Liao et al.
NEUROPSYCHOBIOLOGY (2001)
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia
LS Kegeles et al.
BIOLOGICAL PSYCHIATRY (2000)
Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems
KJA Davies
IUBMB LIFE (2000)
Attenuation of the neuropsychiatric effects of ketamine with lamotrigine -: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists
A Anand et al.
ARCHIVES OF GENERAL PSYCHIATRY (2000)
Placebo-controlled trial of glycine added to clozapine in schizophrenia
AE Evins et al.
AMERICAN JOURNAL OF PSYCHIATRY (2000)
Adjunctive imipramine for a broader group of post-psychotic depressions in schizophrenia
S Siris et al.
SCHIZOPHRENIA RESEARCH (2000)
Share Paper
